Vaccination against cervical cancer and diseases caused by human papillomavirus

Harefuah

Volumn 146, Issue 10, 2007, Pages 764-769

  Bornstein, Jacob ^a   Tuma, Ruba ^a   Zarfati, Doron ^a   Ophir, Ela ^a  

^a WESTERN GALILEE HOSPITAL   (Israel)

Author keywords

Cervical cancer; Genital condylomata acuminata; Human papillomavirus; Vaccine; Virus like particle

Indexed keywords

WART VIRUS VACCINE;

DEVELOPING COUNTRY; FEMALE; HUMAN; IMMUNOLOGY; REVIEW; STATISTICS; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

DEVELOPING COUNTRIES; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 38449114818     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Koutsky LA, Ault KA, Wheeler CM & al, A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med, 2002; 347: 1645-51.
2. Harper DM, Franco EL, Wheeler C & al, Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet, 2004; 364: 1757-65.
3. Villa LL, Costa RL, Petta CA & al, Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol, 2005; 6: 271-78.
4. von Krogh G, Lacey CJ, Gross G & al, European guideline for the management of anogenital warts. Int J STD AIDS, 2001; 12 (Suppl 3): 40-47.
5. Bornstein J, Rabat M & Abramovici H, The etiology of cervical cancer: current concepts. Obstet Gynecol Surv, 1995; 50: 146-154.
6. Bosch FX, Lorincz A, Munoz N & al, The causal relation between human papillomavirus and cervical cancer. J Clin Pathol, 2002; 55: 244-65.
7. Cogliano V, Baan R, Straif K & al, Carcinogenicity of human papillomaviruses. Lancet Oncol, 2005; 6: 931-32.
8. Walboomers JM, Jacobs MV, Manos MM & al, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 1999; 189: 12-19.
9. Silverberg MJ, Thorsen P, Lindeberg H & al, Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol, 2003; 101: 645-652.
10. Munoz N, Bosch FX, De Sanjose S & al, Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 2003; 348: 518-27.
11. Clifford GM, Smith JS, Plummer M & al, Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer, 2003; 88: 63-73.
12. de Villiers EM, Fauquet C, Broker TR & al, Classification of papillomaviruses. Virology, 2004; 324: 17-27.
13. Stanley M, Immune responses to human papillomavirus. Vaccine, 2006; 24: S16-S22.
14. Goldie SJ, Grima D, Kohli M & al, A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer, 2003; 106: 896-904.
15. Parkin DM, Bray F, Ferlay J & Pisani P, Global cancer statistics. CA Cancer J Clin, 2005; 55: 74-108.
16. Munger K & Howley PM, Human papillomavirus immortalization and transformation functions. Virus Res, 2002; 89: 213-228.
17. Daling JR, Madeleine MM, Johnson LG & al, Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer, 2004; 101: 270-280.
18. Hallez S, Simon P, Maudoux F & al, Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother, 2004; 53: 642-650.
19. Corona Gutierrez CM, Tinoco A, Navarro T & al, Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN1, CIN2, and CIN3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther, 2004; 5: 421-431.
20. Hagensee ME, Yaegashi N & Galloway DA, Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol, 1993; 67: 315-322.
21. Kirnbauer R, Taub J, Greenstone H & al, Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol, 1993; 67: 6929-6936.
22. Garcon N, Development and evaluation of AS04, a novel and improved adjuvant system containing MPL and aluminum salt. In: Schijns V & O'Hagan D, (Eds). Immunopotentiators in Modern Vaccines. London: Academic Press, 2005, pp 161-78.
23. Barr E, Assessment and follow-up of HPV vaccines. In: Monsonego J, (Ed). Emerging Issues on HPV Infections, from Science to Pactice. Basel, Karger 2006, pp 227-234.
24. Wideroff L, Schiffman M, Haderer P, et al. Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions. J Infect Dis 1999; 180: 1424-28.
25. Ault KA, Giuliano AR, Edwards RP & al, A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine, 2004; 22: 3004-3007.
26. Munoz N, Efficacy of a quadrivalent HPV (types 6,11,16,18) L1 VLP vaccine against cervical intraepithelial neoplasia grades 1-3 and adenocarcinoma in situ: a combined analysis. Presented at EUROGIN, Paris France May 2006.
27. Harper DM, Franco EL, Wheeler CM & al, Sustained efficacy up to 45 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet, 2006; 367: 1247-55.
28. Harper DM for the FUTURE I Study Group. Oral presentation at: Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA. December 16-19, 2005.
29. Koutsky L for the FUTURE II Study Group. Oral presentation at: Infectious Disease Society of America Annual Meeting; San Francisco, CA. October 6-9, 2005.
30. Mao C, Koutsky L, Ault KA & al, Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia. A randomized controlled trial. Obstet Gynecol, 2006; 107: 18-27.
31. ACOG Committee Opinion: HPV Vaccination. Obstet Gynecol, 2006; 108: 699-705.
32. Editorial, Should HPV vaccines be mandatory for all adolescents? Lancet, 2006; 368: 1212.
33. ACIP recommendations to CDC. Last accessed Sep 11, 2006. http://www.cdc.gov/OD/OC/MEDIA/pressrel/r060629.htm
34. Giannini SL, Hanon E, Moris P & al, Enhanced humoral and memory B cellular immunity using HPV 16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (ASO4) compared to aluminium salt only. Vaccine, 2006; 24: 5937-5949.
35. Ross J, Godeau E, Dias S & al, Health policy for Children and Adolescents, No. 4. 2004: 153-160.
36. Garnett GP, Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis, 2005; 191: S97-S106.
37. Stein R, Cervical cancer vaccine gets injected with a social issue. Washington Post 2005 Page 3A.
38. Dasbach EJ, Elbasha EH & Insinga RP, Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev, 2006; 28: 88-100.
39. Goldie SJ, Kohli M, Grima D & al, Projected clinical benefits and cost effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst, 2004; 96: 604-615.